Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow ALX ONCOLOGY HOLDINGS INC

Get SEC filing alerts via email and in your feed for ALX ONCOLOGY HOLDINGS INC

ALXO

ALX ONCOLOGY HOLDINGS INC

About ALX ONCOLOGY HOLDINGS INC

ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company dedicated to developing innovative cancer therapies. Its lead product, evorpacept, is a next-generation CD47 blocker designed to enhance immune response against tumors while minimizing hematologic toxicities. Targeting solid and hematologic malignancies, ALX is pursuing multiple clinical trials and strategic partnerships to expand treatment options. The company aims to transform cancer care through effective combination therapies and advanced immunotherapy solutions.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from ALX ONCOLOGY HOLDINGS INC

1
1
ALX ONCOLOGY HOLDINGS INC ALX Oncology Reports $17.9M Net Loss, Significant Cash Increase in Latest 10-Q Filing

Via official filing (AI summary) | 28 days ago | 0 comments

2
1
ALX ONCOLOGY HOLDINGS INC ALX Oncology Reports $101.7 Million Net Loss for 2025, Decreases Operating Expenses

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
ALX ONCOLOGY HOLDINGS INC ALX Oncology Reports $22.1 Million Net Loss in Q3 2025, Reduces Operating Expenses by 31%

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
ALX ONCOLOGY HOLDINGS INC ALX Oncology Reports $25.9 Million Net Loss in Q2 2025, Focuses on Clinical Pipeline

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
ALX ONCOLOGY HOLDINGS INC ALX Oncology Reports Q1 2025 Financial Results with $30.8M Net Loss

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
ALX ONCOLOGY HOLDINGS INC ALX Oncology Reports $134.85 Million Net Loss for 2024, Highlights Evorpacept Clinical Trials

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
ALX ONCOLOGY HOLDINGS INC ALX Oncology Reports Improved Financials, Net Loss Reduction, and Strategic Developments in Latest 10-Q Filing

Via official filing (AI summary) | over 1 year ago | 0 comments